Management Presentation

Stock Information

Company Overview

MediPharm Labs brings a pharmaceutical perspective to the cannabis industry, working to internationally recognized pharma-quality standards which result in products that are PURE, TRUSTED and PRECISELY DOSABLE for patients and end consumers.

Company Highlights

  • Primarily focused on producing pharma-grade cannabis oil and concentrates.
  • Fully licensed: Cannabis Oil Production Licence [March 2018] and Cannabis Oil Sales Licence [November 2018]
  • Wholly-owned 70,000 sq ft facility; manufacturing area & laboratories have been constructed to cGMP standards with ISO rated clean rooms and is operational.
  • Pharma-grade critical environments, methodologies and discipline result in repeatability in manufacturing and thus, precision dosing.
  • Current processing capacity of 150,000 kilograms of dry cannabis flower or trim per year; the largest licensed extraction capacities in Canada.
  • Fully funded expansion underway expected to increase customized processing capacity to 250,000 kilograms of dry cannabis per year by Q2 2019.
  • Build-out of critical environment labs and acquisition of state-of-the-art cannabis extraction, fractionation, and distillation equipment completed. Further customization of equipment for proprietary advantage.
  • An agnostic partner to any Licensed Producers, with two revenue streams: White Label Production and Contract Processing.
  • Material revenue generation in Q4 2018 and set to scale rapidly in 2019. 
  • Sales agreements signed with 4 Licensed Producers, including largest wholesale transaction for Cannabis Oil publicly announced to date in the Canadian industry: Sales agreement for 450,000g contracted and an optional additional 450,000g additional cannabis oil to Canopy Growth Corp., the world’s largest cannabis company. This oil will be further processed and sold under their brands.
  • Long-term Cannabis Concentrate Program Agreements are in place with Licensed Producers James E. Wagner Cultivation Corporation, INDIVA Limited, Emerald Therapeutics Inc., The Supreme Cannabis Company and TerrAscend Corp. while in negotiation with several other Licensed Producers.
  • Secured supply agreements for dry cannabis to process from 13 Licensed Producers, notably a long-term supply agreement with UP Cannabis/Newstrike Brands Ltd., as well as numerous bulk wholesale purchases from The Supreme Cannabis Company, and The Cronos Group among others.
  • Named as one of only 32 Licensed Producer suppliers for the Ontario Cannabis Stores.
  • MediPharm Labs has rights and plans to open four retail stores in the province of Manitoba in 2019 through its Joint Venture Partnership “Garden Variety” with Avana Canada Inc. of Ontario, Fisher River Cree Nation of Manitoba, Chippewas of the Thames of Ontario.
  • Research-driven, bio-pharmaceutical team led by Dr. Chris Talpas, Director of Quality Control and Assurance, renowned chromatography expert. Dr. Ina Dubinsky is the lead scientist for our Secondary Processing (Short-Path Distillation and Centrifugal Chromatography).
  • MediPharm Labs Australia PTY facility, which is a purpose-built, state-of-the-art extraction facility designed to produce the same superior pharmaceutical grade cannabis oil as the Company’s purpose-built Health Canada licensed cannabis oil production facility and laboratories in Barrie, Ontario is under development and is anticipated to be operational in spring 2019 pending licensing. MediPharm Labs’ Australian facility in Wonthaggi is expected to serve both the Australian domestic market as well as facilitate international supply chain and logistics opportunities, subject to receipt of applicable licences.
  • Development of additional specialized intellectual property, focused on downstream proprietary fractionation, isolation and chromatography underway.
  • Advanced activities underway targeting strategic partnerships, development of proprietary products and international opportunities.
  • Last private financing targeted at $15 million. Oversubscribed to $22.225 million.
  • MMJ PhytoTech Limited and PowerOne Capital Markets Limited are strategic shareholders. MediPharm Labs has been added to Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ).
  • Management owns shares and has increased share holdings and investment in the company over time.
  • First full year of profitability and a top five cannabis revenue company in the Canadian Cannabis industry.
  • Signed multiple new supplier agreements with other Cannabis Act licensed holders, direct-to-consumer brands, provincial and private retailers including Medical Cannabis by Shoppers (2020); first international export agreements with AusCann Group Holdings Ltd., an Australian medicinal cannabis company, and ADREXpharma GmbH, a German pharmaceutical distributor.
  • Received first GMP certification by the Therapeutic Goods Administration of Australia (TGA) and completed its subsidiary’s offshore facility in Australia.
  • Successful ramp up of the Company’s operations to support customers in the development and introduction of a range of Cannabis 2.0 products; first shipments delivered prior to year-end.
  • Successful shipment of the Company’s first international exports of wholesale cannabis extract to Australia.
  • Achieved a Research Licence and conducted its first controlled human administration trials in Barrie.
  • Expanded licensed facility footprint, to 25,000 sq. ft. to scale up automated downstream production, packaging and R&D supporting fulfillment of new product formats and formulation orders in 2020.


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


MediPharm Labs Corp.
151 John St.
Barrie, ON L4N 2L1
T: +1 705 719 7425

Investor Relations

MediPharm Labs Corp.
151 John St.
Barrie, ON L4N 2L1
T: 416-913-7425 ext 1525
[email protected]

Transfer Agent

TSX Trust Company